IET London: Savoy Place London, WC2R 0BL | 3rd-4th December 2024
Building a multibillion-dollar synthetic biology industry with positive impact
About Us
About SynbiTECH
SynbiTECH is the UK’s leading international forum for people engaged in engineering biology (synthetic biology) business, investment, policymaking, science and research.
Running for the fifth time, this major UK synthetic biology business conference will attract more than 400 delegates and speakers, bringing together the best and brightest minds in SynBio, sustainability and business innovation.
The Event
Why attend SynbiTECH 2024?
SynbiTECH is the UK’s leading synthetic biology conference. We are dedicated to fostering innovation in synbio, bringing together visionary leaders and industry experts. Our focus is on delivering a content-rich program featuring speakers who can provide transformative insights.
Don’t miss your chance to join the event and post your questions to our global synthetic biology leaders. With the fast-growing global population, our rapid use of the world’s finite resources and the damaging impacts of climate change on the environment.
Forge connections with peers, potential clients, policy experts, investors and collaborators while enjoying the spectacular views of London’s iconic architecture from the stunning IET London in Savoy Place.
The Venue
IET London: Savoy Place
IET London: Savoy Place – the home of cutting-edge engineering and technology. This historic central London event venue on the River Thames offers cutting edge technology, improved capacity and outside space in a location that’s easily accessible by rail, tube and river.
Speakers
SynbiTECH 2024 speakers
-
Jens Nielsen
BioInnovation Institute
Jens is the CEO of the BioInnovation Institute.Jens Nielsen
BioInnovation Institute
Bio
MSc in Chemical Engineering, PhD (1989) in Biochemical Engineering and dr.techn. (1995) from the Danish Technical University (DTU). Honorable dr.med. from University of Gothenburg. Fulbright visiting professor at MIT in 1995-1996. Professor at DTU in 1998. In 2008 he was recruited as Professor to Chalmers University of Technology, Sweden. In 2015 he was founding Head of the Department of Life Sciences, which now encompass more than 250 people. Jens Nielsen was also a co-founder of the Novo Nordisk Foundation Center for Biosustainability that now has more than 300 people affiliated, for which he served as CSO 2013-2018. From 2019 CEO of the BioInnovation Institute in Denmark, which is a new institute financed by USD500M that fosters translational research and support new spin-out companies in life sciences. He has trained more than 280 scientists in his research group and published >850 publications that have been cited more than 126,000 times (current H-factor 162). Inventor of >50 patents and founder of six biotech companies. Has received numerous awards, including the ENI Award, the Eric and Sheila Samson Prime Minister Prize for Transportation Fuels, the Novozymes Prize, and the Gold Medal from the Royal Swedish Academy of Engineering Sciences. Member of 13 academies, including NAS, NAE, NAM, Chinese Academy of Engineering, EMBO and Royal Swedish Academy of Science.
-
Susan Rosser
UK Centre for Mammalian Synthetic Biology
Susan is the Director of the UK Centre for Mammalian Synthetic Biology and Co-director of the Edinburgh Genome Foundry for synthetic DNA synthesis and assembly.Susan Rosser
UK Centre for Mammalian Synthetic Biology
Bio
Susan is Professor of Synthetic Biology and Royal Academy of Engineering (RAEng) Chair in Emerging Technologies at the University of Edinburgh. She is Director of the UK Centre for Mammalian Synthetic Biology and Co-director of the Edinburgh Genome Foundry for synthetic DNA synthesis and assembly. She also held a prestigious Engineering and Physical Sciences Research Council (EPSRC) Leadership Fellowship in Synthetic Biology. In 2022, her work was recognised by the national academies of both Scotland and Wales, being elected as a Fellow of the Royal Society of Edinburgh (RSE) and Fellow of the Learned Society of Wales. She served as a member of the Scottish Science Advisory Council, Scotland’s highest level science advisory body, providing independent advice and recommendations on science strategy, policy and priorities to the Scottish Government. Her research focuses on using synthetic biology approaches for developing and controlling genetic circuits for applications in cell and gene therapies as well as metabolic engineering. She is co-founder of two early-stage start-ups using a combination of AI and engineering biology for new gene therapies and enzyme replacement therapies for rare diseases.
-
Rodrigo Ledesma Amaro
UKRI Engineering Biology Mission Hub on Microbial Food
Rodrigo is the director of the UKRI Engineering Biology Mission Hub on Microbial Food.Rodrigo Ledesma Amaro
UKRI Engineering Biology Mission Hub on Microbial Food
Bio
Rodrigo Ledesma-Amaro is leading a research group at the interface of synthetic biology and metabolic engineering at Imperial College London. He is interested in using microbial cells to produce sustainable foods, fuels, pharmaceuticals and materials. His research covers the generation of cutting-edge synthetic biology tools such as novel CRISPR tools, the production of compounds of interest such as foods, fuels, chemicals in engineered microorganisms and the exploration of complex microbial communities and their role in improved bioprocesses. Rodrigo is the director of the UKRI Engineering Biology Mission Hub on Microbial Food.
-
Christina Smolke
Antheia, Inc
Christina Smolke is CEO and co-founder of Antheia, Inc. and Adjunct Professor of Bioengineering at Stanford UniversityChristina Smolke
Antheia, Inc
Bio
Dr. Smolke, a pioneer in the fields of synthetic biology and metabolic engineering, joined Caltech’s faculty in 2003 as an Assistant Professor of Chemical Engineering and joined Stanford’s faculty in 2009, where she was Professor of Bioengineering. Dr. Smolke’s early work pioneered the design and application of a broad class of RNA molecules, RNA switches, that detect chemical signals and regulate targeted protein activities, providing programmable platforms for building biological sensors and control systems. At Stanford, her team led the breakthrough research to engineer baker’s yeast to produce some of the most complex and valuable plant-based essential medicines known to humankind. At Antheia, her vision and leadership has enabled a synthetic biology platform that dramatically expands the diversity and complexity of molecules that can be reconstructed, enabling new possibilities for drug discovery as well as efficient, sustainable, transparent, on-demand drug manufacturing at scale.
Dr. Smolke’s impact in advancing the frontiers of biotechnology has been recognized with numerous awards, including Chan Zuckerberg Biohub Investigator, Nature’s 10, AIMBE College of Fellows, NIH Director’s Pioneer Award, NSF Career Award, Novozymes Award for Excellence in Biochemical Engineering, WTN Award in Biotechnology, and TR35 Award.
Sponsorship
Looking to sponsor SynbiTECH 2024?
Sponsors will be given prized exposure at the heart of the event through dedicated meeting points in high traffic areas of the venue.
Become a key player in SynbiTECH 2024 and present your company to a highly engaged global customer base at this year’s event.
Sign up for updates
Sign up to receive the latest updates and special offers from SynbiTECH